查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715678

微生物组治疗市场按产品、治疗领域、配方、来源、最终用途和分销管道划分－2025-2030 年全球预测

Microbiome Therapeutics Market by Products, Therapeutic Area, Formulation, Source, End-use, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

微生物组治疗市场预计 2023 年将达到 9.8802 亿美元，2024 年将达到 11.1894 亿美元，复合年增长率为 14.45%，到 2030 年将达到 25.4245 亿美元。

主要市场统计数据
基准年2023年 9.8802亿美元
预计2024年 1,118,940,000美元
预测年份 2030 2,542,450,000美元
复合年增长率（%） 14.45%

微生物组疗法是医疗保健领域的变革前沿，透过操纵微生物生态系统为长期存在的医疗挑战提供创新解决方案。近年来，科学的突破开启了旨在恢復人体平衡的标靶治疗的新时代。这种方法不仅为透过新机制治疗慢性和急性疾病铺平了道路，而且挑战了药物开发的传统范式。该领域的进步是由尖端研究、不断增加的投资以及越来越多的检验微生物干预潜力的临床证据共同推动的。随着研究的进展和微生物组的复杂性变得更加清晰，决策者和相关人员有独特的机会将这些新治疗方法整合到标准治疗方法中。本介绍概述说明探讨了市场动态、策略性细分以及区域发展对微生物组疗法未来的影响。

改变微生物组治疗市场

微生物组治疗领域正在经历变革时期，重新定义医疗保健创新的轮廓。分子生物学和基因组学的进步揭示了微生物群落对人类健康的作用，从而带来了新的治疗方法和手段的出现。法律规范也在不断发展，以跟上快速的技术创新，使研究成果能够更快地转化为临床实践。此外，加强学术界、生技公司和监管机构之间的跨部门合作对于促进创新和确保新治疗方法符合安全性和有效性标准至关重要。数位化和数据分析也在改变临床试验的设计和实施方式方面发挥关键作用，使患者细分和治疗个人化成为可能。这种转变不仅突破了传统药物开发的界限，而且还带来了强调灵活性和以患者为中心的新型经营模式。随着相关人员重新考虑其投资重点和研究策略，人们感受到了微生物组疗法重塑全球医疗保健服务的潜力。

微生物组治疗市场动态的关键细分洞察

对市场区隔的详细分析揭示了一个复杂且多方面的生态系统，这对于理解推动整体微生物组治疗成长的因素至关重要。按产品检验市场，粪便微生物群移植、活生物治疗、微生物组药物、微生物组生态系统疗法和益生菌/益生元等领域正受到关注，每个领域都有各自的优势和挑战。治疗领域涵盖广泛的适应症，包括自体免疫疾病、癌症、胃肠病学、感染疾病、代谢疾病和神经系统疾病，确保创新能转化为广泛的临床应用。此外，主要由口服和外用药物组成的製剂部分反映了现代患者照护和治疗依从性的动态要求。微生物组疗法的来源也起着关键作用，动物、环境和人类微生物组之间的区别都导致了不同的治疗途径。按最终用途评估市场突出了学术和研究机构以及医院和诊所参与推动这些治疗方法的临床检验和实用化。最后，分销管道分为线下药局和线上药局，线下部分进一步细分为医院药局和零售药局，形成一个复杂的网络，确保广泛的覆盖率和强大的市场渗透力。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 文明病的盛行率不断上升
      • 政府对微生物组研究和商业化的措施和资助
    • 限制因素
      • 微生物组治疗产品召回的潜在风险
    • 机会
      • 利用微生物组疗法促进女性荷尔蒙和生殖健康
      • 增加对人工智慧驱动的微生物组疗法的投资
    • 任务
      • 与微生物组数据收集和治疗用途相关的伦理和隐私问题
  • 市场区隔分析
    • 产品：针对慢性疾病的针对性介入对微生物组疗法的需求不断增长
    • 治疗领域：自体免疫疾病对微生物组药物的需求不断增加，以减少发炎和调节免疫反应
    • 製剂：治疗胃肠道疾病的口服製剂需求不断增长
    • 资料来源：继续研究利用动物微生物组了解肠脑轴和免疫调节
    • 最终用途：微生物组治疗在学术创新中的演变
    • 交付管道：大力部署透过线上管道交付微生物组疗法
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 微生物组治疗市场（依产品）

  • 粪便微生物移植
  • 活体生物治疗公司
  • 微生物组医学
  • 微生物生态系疗法
  • 益生菌和益生元

7. 微生物组治疗市场（依治疗领域）

  • 自体免疫疾病
  • 癌症
  • 胃肠道疾病
  • 感染疾病
  • 代谢紊乱
  • 神经系统疾病

8. 微生物组治疗市场（按剂型）

  • 口服
  • 话题

9. 微生物组治疗市场（依来源）

  • 动物微生物组
  • 环境微生物组
  • 人类微生物组

第 10 章微生物组治疗市场（依最终用途）

  • 学术研究所
  • 医院和诊所

第 11 章微生物组治疗市场（依通路）

  • 离线
    • 医院药房
    • 零售药局
  • 网路药局

12. 美国微生物医学治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13. 亚太地区微生物组治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14. 欧洲、中东和非洲微生物组治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Alveolus Bio, Inc. by ResBiotic
  • AOBiome LLC
  • Assembly Biosciences, Inc.
  • Axial Therapeutics, Inc.
  • BioGaia AB
  • BiomeBank
  • EnteroBiotix Ltd
  • Enterome SA
  • Ferring BV
  • Intralytix, Inc.
  • Kanvas Biosciences
  • Locus Biosciences, Inc.
  • MaaT Pharma SA
  • Microba Life Sciences Limited
  • Microbiotica Ltd.
  • MRM Health NV
  • NuBiyota
  • Osel, Inc.
  • Pendulum Therapeutics
  • PharmaBiome AG
  • Pylum Biosciences
  • Seres Therapeutics, Inc.
  • Servatus Limited
  • Siolta Therapeutics
  • Theriva Biologics, Inc.
  • Vedanta Biosciences, Inc.
  • Viome Life Sciences, Inc. by BlueDot LLC
  • Xbiome Co. Ltd.
Product Code: MRR-ED54C46E807C

The Microbiome Therapeutics Market was valued at USD 988.02 million in 2023 and is projected to grow to USD 1,118.94 million in 2024, with a CAGR of 14.45%, reaching USD 2,542.45 million by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 988.02 million
Estimated Year [2024] USD 1,118.94 million
Forecast Year [2030] USD 2,542.45 million
CAGR (%) 14.45%

Microbiome therapeutics represents a transformative frontier in healthcare where the manipulation of microbial ecosystems offers innovative solutions to longstanding medical challenges. In recent years, significant scientific breakthroughs have propelled the industry into a new era of targeted therapies aimed at restoring balance in the human body. This approach not only opens avenues for addressing chronic and acute diseases through novel mechanisms but also challenges traditional paradigms in drug development. The field's progression is underpinned by a combination of cutting-edge research, increasing investments, and a growing body of clinical evidence that validates the potential for microbial interventions. As research continues to unveil the complexities of microbiomes, decision-makers and stakeholders are presented with unique opportunities to integrate these emerging treatments into standard therapeutic regimens. This introductory overview sets the stage for an in-depth exploration of market dynamics, strategic segmentation, and the impact of regional developments that collectively shape the future of microbiome therapeutics.

Transformative Shifts in the Microbiome Therapeutics Landscape

The microbiome therapeutics landscape is undergoing transformative shifts that are redefining the contours of healthcare innovation. Advances in molecular biology and genomics have clarified the role of microbial communities in human health, leading to a surge of novel therapeutic approaches and treatment modalities. Regulatory frameworks are evolving to keep pace with rapid innovation, enabling faster translation of research insights into clinical practice. Furthermore, increased cross-sector collaboration between academia, biotechnology companies, and regulatory bodies is instrumental in fostering innovation and ensuring that emerging therapies meet both safety and efficacy standards. Digitalization and data analytics are also playing pivotal roles in transforming how clinical trials are designed and executed, allowing for more precise patient segmentation and treatment personalization. These shifts are not only pushing the boundaries of traditional drug development but are also inviting new business models that emphasize agility and patient-centric care. As stakeholders reconsider investment priorities and research strategies, there is a palpable momentum that underscores the potential for microbiome therapeutics to reshape global healthcare delivery.

Key Segmentation Insights on Market Dynamics in Microbiome Therapeutics

A detailed analysis of the market segmentation reveals a complex and multifaceted ecosystem that is critical to understanding the growth drivers across microbiome therapeutics. When examining the market based on products, considerable attention is given to areas such as Fecal Microbiota Transplantation, Live-Biotherapeutics, Microbiome Drugs, Microbiome Ecosystem Therapies, and Probiotics & Prebiotics, each offering unique advantages and challenges. The therapeutic areas span a wide array of indications including Autoimmune Diseases, Cancer, Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, and Neurological Disorders, ensuring that innovations have broad clinical applications. In addition, the formulation segment, comprising mainly oral and topical solutions, reflects the dynamic requirements of modern patient care and treatment compliance. The source of microbiome therapies also plays a pivotal role, with distinctions between Animal Microbiome, Environmental Microbiome, and Human Microbiome all contributing to diverse therapeutic pathways. Evaluating the market by end-use highlights the involvement of both Academic & Research Institutions and Hospitals & Clinics, which drive clinical validation and practical application of these therapies. Finally, the distribution channel is bifurcated into Offline and Online Pharmacies, with the offline segment further differentiated by Hospital Pharmacies and Retail Pharmacies, together creating an intricate network that ensures wide accessibility and robust market penetration.

Based on Products, market is studied across Fecal Microbiota Transplantation, Live-Biotherapeutics, Microbiome Drugs, Microbiome Ecosystem Therapies, and Probiotics & Prebiotics.

Based on Therapeutic Area, market is studied across Autoimmune Diseases, Cancer, Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, and Neurological Disorders.

Based on Formulation, market is studied across Oral and Topical.

Based on Source, market is studied across Animal Microbiome, Environmental Microbiome, and Human Microbiome.

Based on End-use, market is studied across Academic & Research Institutions and Hospitals & Clinics.

Based on Distribution Channel, market is studied across Offline and Online Pharmacies. The Offline is further studied across Hospital Pharmacies and Retail Pharmacies.

Key Regional Insights: Global Trends in Microbiome Therapeutics

The global landscape of microbiome therapeutics is marked by distinctive regional trends that underline both the maturity and growth potential of the industry. In the Americas, robust infrastructure and significant investments in biotechnology, combined with an active ecosystem of research collaboration, have positioned the region as a leader in both innovation and commercialization efforts. Meanwhile, the Europe, Middle East & Africa region displays a blend of established regulatory environments and emerging markets, creating a fertile ground for local and international partnerships. This diversity is evident in the way innovative practices are balanced with traditional healthcare systems to deliver patient-centric interventions. In the Asia-Pacific region, rapid economic growth and a surge in healthcare investments coupled with a high demand for advanced therapeutic solutions have spurred an increase in clinical research and adoption of microbiome-based treatments. Each of these regions presents unique market dynamics - from regulatory nuances to varied patient needs - that collectively drive global competitiveness and investment in microbiome therapeutics.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights: Market Leaders Driving Innovation

A thorough exploration of the competitive landscape in microbiome therapeutics reveals a robust cadre of companies that are at the forefront of innovation. Key players include Alveolus Bio, Inc. by ResBiotic, AOBiome LLC, Assembly Biosciences, Inc., Axial Therapeutics, Inc., and BioGaia AB, among others. Companies such as BiomeBank, EnteroBiotix Ltd, Enterome SA, and Ferring B.V. have demonstrated a sustained commitment to developing therapies that leverage microbial dynamics to combat disease. In addition, innovators like Intralytix, Inc., Kanvas Biosciences, Locus Biosciences, Inc., and MaaT Pharma SA are actively contributing to the diversification of product portfolios in the market. This ingenuity is further echoed by players such as Microba Life Sciences Limited, Microbiotica Ltd., MRM Health NV, NuBiyota, and Osel, Inc., as they navigate regulatory environments and continue to refine therapeutic formulations. Additionally, companies like Pendulum Therapeutics, PharmaBiome AG, Pylum Biosciences, Seres Therapeutics, Inc., Servatus Limited, Siolta Therapeutics, and Theriva Biologics, Inc. are forging new pathways in clinical development. The landscape is rounded out by Vedanta Biosciences, Inc., Viome Life Sciences, Inc. by BlueDot LLC, and Xbiome Co. Ltd., whose strategic initiatives and commitment to research excellence underscore the competitive intensity and growth prospects within the sector.

The report delves into recent significant developments in the Microbiome Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alveolus Bio, Inc. by ResBiotic, AOBiome LLC, Assembly Biosciences, Inc., Axial Therapeutics, Inc., BioGaia AB, BiomeBank, EnteroBiotix Ltd, Enterome SA, Ferring B.V., Intralytix, Inc., Kanvas Biosciences, Locus Biosciences, Inc., MaaT Pharma SA, Microba Life Sciences Limited, Microbiotica Ltd., MRM Health NV, NuBiyota, Osel, Inc., Pendulum Therapeutics, PharmaBiome AG, Pylum Biosciences, Seres Therapeutics, Inc., Servatus Limited, Siolta Therapeutics, Theriva Biologics, Inc., Vedanta Biosciences, Inc., Viome Life Sciences, Inc. by BlueDot LLC, and Xbiome Co. Ltd.. Actionable Recommendations for Leading Industry Stakeholders

For industry stakeholders keen on harnessing the potential of microbiome therapeutics, several actionable recommendations can serve as a roadmap for sustained success and market leadership. First, it is crucial to invest in robust research and development programs that focus on the translational aspects of innovative microbiome therapies. Companies should streamline clinical trials and adopt adaptive study designs to accelerate regulatory approvals while mitigating risks related to therapeutic efficacy and safety. Second, fostering strategic partnerships across academic institutions, clinical research centers, and biotech innovators can create synergistic benefits that drive both discovery and market entry processes. Stakeholders should consider joint ventures and collaborative frameworks that facilitate the exchange of scientific insights, ultimately leading to a faster commercialization cycle. Third, aligning investment strategies with emerging patient needs, particularly in areas such as autoimmune diseases, cancer, and gastrointestinal disorders, will help companies tailor their products to a rapidly evolving market. In addition, leveraging digital health tools and data analytics can enhance market segmentation strategies by providing deeper insights into patient demographics and treatment responses. Finally, a proactive approach to navigating the regulatory landscape, with a strong focus on compliance and quality assurance, remains critical in ensuring that innovations are not only groundbreaking but also widely accessible and safe for public use.

Concluding Perspectives on the Future of Microbiome Therapeutics

In conclusion, the field of microbiome therapeutics stands at the intersection of unprecedented scientific discovery and the urgent need for innovative healthcare solutions. The collective insights derived from comprehensive market segmentation, regional trends, and competitive analysis underscore the immense potential of microbial therapies in reshaping the future of medicine. With robust advancements in research and development, coupled with an adaptive regulatory framework, stakeholders have a unique opportunity to address unmet clinical needs and pioneer new therapeutic paradigms. The ongoing evolution of product modalities, from fecal microbiota transplantation and live-biotherapeutics to microbiome drugs and ecosystem therapies, is testament to the depth and diversity within the market. Meanwhile, the convergence of academic research, clinical practice, and strategic investment sets the stage for continued growth and innovation. As the industry moves forward, a balanced approach that emphasizes collaboration, digital integration, and patient-centricity will be critical in unlocking the full potential of microbiome therapeutics and ensuring that these advancements translate into tangible societal benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the prevalence of lifestyle-associated diseases
      • 5.1.1.2. Government initiatives and funding for microbiome research and commercialization
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of product recalls in microbiome therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging microbiome therapeutics for hormonal and reproductive health of women
      • 5.1.3.2. Growing investment in AI-driven microbiome-based therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical and privacy concerns linked with microbiome data collection and usage in treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Products: Rising need of microbiome therapeutics for targeted interventions in chronic diseases
    • 5.2.2. Therapeutic Area: Growing demand of microbiome therapeutics in autoimmune diseases for reducing inflammation and modulating immune responses
    • 5.2.3. Formulation: Growing demand for oral formulations to address gastrointestinal conditions
    • 5.2.4. Source: Ongoing research for the use of animal microbiomes in understanding the gut-brain axis and immune modulation
    • 5.2.5. End-use: The evolving landscape of microbiome therapeutics for academic innovations
    • 5.2.6. Distribution Channel: Thriving microbiome therapeutics distribution through online channels
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Microbiome Therapeutics Market, by Products

  • 6.1. Introduction
  • 6.2. Fecal Microbiota Transplantation
  • 6.3. Live-Biotherapeutics
  • 6.4. Microbiome Drugs
  • 6.5. Microbiome Ecosystem Therapies
  • 6.6. Probiotics & Prebiotics

7. Microbiome Therapeutics Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
  • 7.3. Cancer
  • 7.4. Gastrointestinal Disorders
  • 7.5. Infectious Diseases
  • 7.6. Metabolic Disorders
  • 7.7. Neurological Disorders

8. Microbiome Therapeutics Market, by Formulation

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Topical

9. Microbiome Therapeutics Market, by Source

  • 9.1. Introduction
  • 9.2. Animal Microbiome
  • 9.3. Environmental Microbiome
  • 9.4. Human Microbiome

10. Microbiome Therapeutics Market, by End-use

  • 10.1. Introduction
  • 10.2. Academic & Research Institutions
  • 10.3. Hospitals & Clinics

11. Microbiome Therapeutics Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Offline
    • 11.2.1. Hospital Pharmacies
    • 11.2.2. Retail Pharmacies
  • 11.3. Online Pharmacies

12. Americas Microbiome Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Microbiome Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Microbiome Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Kester Capital fuels growth for EMAS pharma in expanding CRO market
    • 15.3.2. AstraZeneca's USD 3.5 billion investment boosts microbiome therapeutics innovation in United States
    • 15.3.3. Biohm and ADM launch vivifem for targeted microbiome support in aging women
    • 15.3.4. Zymo Research and BluMaiden unite for advanced microbiome clinical analytics
    • 15.3.5. Nexilico and Siolta Therapeutics forge collaboration to advance treatments for infant NEC
    • 15.3.6. Metagen Therapeutics partners with JSR Corporation to establish an FMT drug manufacturing facility in Japan
    • 15.3.7. Seed Health expands retail presence with launch of probiotics in target stores nationwide
    • 15.3.8. Pendulum Therapeutics and BiomeSense unveiled microbiome research with continuous monitoring of Akkermansia muciniphila
    • 15.3.9. Kanvas Biosciences raised USD 12.5 million to progress microbiome-based immuno-oncology therapies
    • 15.3.10. Biolog, Inc. unveiled PreBioM microplates to advance gut microbiome characterization
    • 15.3.11. Nature Awards and Seed Health unite to launch microbiome accelerator solutions
    • 15.3.12. Seres Therapeutics enhanced the VOWST and achieved FDA Fast Track for SER-155
    • 15.3.13. Ferring B.V. signs partnership with PharmaBiome for development of microbiome-based therapies for gastrointestinal conditions
    • 15.3.14. Persephone Biosciences and Ginkgo Bioworks collaborate to enhance Bacteroides engineering for therapeutics development
    • 15.3.15. Microbiome Therapeutics Innovation Group expanded by joint venture with MaaT Pharma
  • 15.4. Strategy Analysis & Recommendation
    • 15.4.1. Enterome SA
    • 15.4.2. Xbiome Co. Ltd.
    • 15.4.3. Ferring B.V.
    • 15.4.4. Seres Therapeutics, Inc.

Companies Mentioned

  • 1. Alveolus Bio, Inc. by ResBiotic
  • 2. AOBiome LLC
  • 3. Assembly Biosciences, Inc.
  • 4. Axial Therapeutics, Inc.
  • 5. BioGaia AB
  • 6. BiomeBank
  • 7. EnteroBiotix Ltd
  • 8. Enterome SA
  • 9. Ferring B.V.
  • 10. Intralytix, Inc.
  • 11. Kanvas Biosciences
  • 12. Locus Biosciences, Inc.
  • 13. MaaT Pharma SA
  • 14. Microba Life Sciences Limited
  • 15. Microbiotica Ltd.
  • 16. MRM Health NV
  • 17. NuBiyota
  • 18. Osel, Inc.
  • 19. Pendulum Therapeutics
  • 20. PharmaBiome AG
  • 21. Pylum Biosciences
  • 22. Seres Therapeutics, Inc.
  • 23. Servatus Limited
  • 24. Siolta Therapeutics
  • 25. Theriva Biologics, Inc.
  • 26. Vedanta Biosciences, Inc.
  • 27. Viome Life Sciences, Inc. by BlueDot LLC
  • 28. Xbiome Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. MICROBIOME THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. MICROBIOME THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. MICROBIOME THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. MICROBIOME THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. MICROBIOME THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. MICROBIOME THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MICROBIOME THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MICROBIOME THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FECAL MICROBIOTA TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY LIVE-BIOTHERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY MICROBIOME DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY MICROBIOME ECOSYSTEM THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ANIMAL MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ENVIRONMENTAL MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HUMAN MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 327. MICROBIOME THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 328. MICROBIOME THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023